Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful

April 3, 2012

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor. This data will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held from Saturday through Wednesday (March 31- April 4) in Chicago, IL.

It is estimated that there will be 22,280 new cases and 15,500 deaths this year from ovarian cancer in the United States. Due to lack of adequate screening, the majority of patients with ovarian cancer are diagnosed at stage III (the second-to-last and most devastating stage of cancer), when 70 percent of these patients will die of their disease within 5 years.

"The discovery that microRNAs can help predict the best treatment plan for women with ovarian cancer, who are most likely at stage III of the disease, offers them enormous hope," noted Iuliana Shapira, MD, director of the Cancer Genetics Program at the North Shore-LIJ Health System's Monter Cancer Center. "We can now inform patients at ovarian cancer, if they will have success with chemotherapy following surgery, similar to patients who are at stage 1 disease. This information gives them hope that their disease is curable despite being diagnosed at an 'advanced stage.' It also gives them the strength necessary to undergo chemotherapy, which is a very invasive and toxic therapy necessary to obtain the cure."

Several microRNAs have been found to have links with various . The research conducted at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research found that microRNA-195 increased 40 fold during chemotherapy and microRNA-16 increased 80 fold during chemotherapy. These changes may explain why some patients with ovarian cancer have side effects of chemotherapy, why others become cured of cancer as a result of chemotherapy, and why others need ongoing chemotherapy to continue living with the cancer.

"Understanding the changes in microRNA throughout chemotherapy treatment helps us better understand ovarian cancer and how best to treat patients who have this disease," said Annette Lee, PhD, associate investigator at the Feinstein Institute. "The genetic markers we identified allow patients to individualize their own therapy in order to have maximum benefit and minimal side effects. In addition, this knowledge will help researchers develop new treatments for patients with ."

Dr. Shapira adds that, "We applied for a government grant and hope to receive the funds needed to validate these markers allow result in women receiving therapies that are more personalized and match their genetic makeup."

Explore further: New drug combination slows tumor growth for recurrent ovarian cancer

Related Stories

New drug combination slows tumor growth for recurrent ovarian cancer

June 6, 2011
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...

Tiny genetic variation can predict ovarian cancer outcome

December 5, 2011
Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

December 20, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that the commonest type of ovarian cancer evolves at a startling rate, which may allow cancer cells to ‘dodge’ the current standard treatment, reveals ...

Researchers find possible key to preventing chemotherapy resistance in ovarian cancer

September 15, 2011
For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.